SBRT: Revolutionizing Cancer Treatment?
"Unpacking the Latest Advances in Stereotactic Body Radiation Therapy for Lung and Prostate Cancer"
Stereotactic Body Radiation Therapy (SBRT) has emerged as a significant advancement in cancer treatment, offering a precise and effective approach to targeting tumors while minimizing damage to surrounding healthy tissues. This technique is particularly valuable for patients with localized tumors who may not be suitable candidates for surgery or prefer a non-invasive treatment option.
Two key areas where SBRT has shown considerable promise are in the treatment of lung and prostate cancer. In lung cancer, SBRT is used for both primary early-stage non-small cell lung cancer (NSCLC) and local relapses following surgery. For prostate cancer, SBRT offers an alternative to traditional radiation therapy, with the goal of delivering high doses of radiation to the tumor while sparing the rectum and other nearby organs.
This article will explore the latest research on SBRT for lung and prostate cancer, highlighting the benefits, challenges, and ongoing efforts to optimize treatment protocols. We will delve into the importance of credentialing in lung SBRT, as well as the dosimetric considerations for achieving optimal rectal sparing in prostate cancer SBRT. Understanding these aspects is crucial for healthcare professionals and patients alike, as SBRT continues to evolve and play an increasingly important role in cancer management.
Utilization and Long-Term Evidence
A 2025 study of single-fraction SBRT reports promising tolerability and high local-control rates, but says long-term outcome data and evidence to guide treatment by patient or tumor characteristics remain limited. A separate study published in 2026 set out to assess U.S. SBRT utilization trends and coded reasons some patients treated with SBRT did not undergo surgery. A 2025 study also specifically examined 15-year trends in single-fraction SBRT use for early-stage non-small cell lung cancer (NSCLC).
Established Use and Expanding Questions
SBRT is considered a standard-of-care treatment for people with inoperable early-stage NSCLC and for lung metastases. It delivers ablative radiation precisely without an invasive procedure, and its use and availability have increased over the past decades. Its application is expanding to more complex patient groups who may face higher risks of treatment-related toxicity, while evidence beyond the foundational patient populations remains an active area of interest.
From Intracranial SRS to Body Treatment
The development of SBRT for tumors outside the brain drew on clinical experience with intracranial stereotactic radiosurgery (SRS) and technical advances in conventional radiation therapy. This combination enabled a treatment approach characterized by a very high radiation dose per fraction delivered over a short time. Clinical use of SBRT for inoperable early-stage NSCLC increased dramatically over the two decades described in a 2019 review, which identified it as the standard of care in that setting.
Lung SBRT: Credentialing and Consistency in Treatment Delivery
A study was conducted in Canada to assess the variability in lung SBRT practice among different centers. The OCOG-LUSTRE trial (NCT01968941) compared SBRT to conventionally hypofractionated radiation for stage I medically inoperable NSCLC. A key component of this trial was a comprehensive credentialing process aimed at ensuring consistent and high-quality treatment delivery across all participating centers.
- Completing an institutional survey detailing treatment protocols, dosimetry practices, and image guidance equipment.
- Demonstrating acceptable delivery accuracy using the Imaging and Radiation Oncology Core (IROC) thoracic phantom.
- Successfully contouring and completing standardized test cases for both central and peripheral NSCLC tumors.
Peer Review Priorities for Lung Radiation
A study on peer review practices for lung radiation therapy identified six essential review elements for its locally advanced (LA) case. These were the indications for radiation therapy, gross tumor volume (GTV), clinical target volume (CTV), internal target volume (ITV), dose and fractionation, and normal-lung dosimetry. The findings describe specific components reviewers considered essential when evaluating the case.
Uncertainties in Outcomes and Failure Patterns
SBRT is established as the standard of care for medically inoperable early-stage NSCLC, but long-term outcomes and patterns of failure after empiric treatment remain underreported when biopsy is not feasible. A systematic review addressed evidence on single-fraction SBRT by examining prospective studies of definitive treatment for early-stage and oligometastatic lung cancer. A 2025 study of single-fraction SBRT in patients with NSCLC ineligible for surgery likewise set out to investigate long-term clinical outcomes and prognostic factors.
Comparing SBRT and Surgery
Surgical resection is described as the standard curative treatment for stage I NSCLC, while SBRT is an established alternative for patients who are medically inoperable or decline surgery. Interest in directly comparing SBRT with surgery in operable patients has been constrained by early randomized trials that closed because of poor accrual. A 2019 cohort study compared long-term overall survival among patients with early-stage NSCLC treated with SBRT.
The Future of SBRT: Balancing Precision and Individualized Care
SBRT is rapidly becoming a cornerstone of modern cancer treatment, offering a non-invasive and highly targeted approach to tumor control. As technology advances and our understanding of cancer biology deepens, SBRT is likely to become even more precise and effective.
Precision and Healthy-Tissue Preservation
A 2024 review characterizes SBRT as a sophisticated radiation approach that delivers exceptionally precise, potent doses to tumor sites while seeking to preserve surrounding healthy tissue. The review frames this combination of targeted treatment and tissue preservation as a defining feature of the approach.
Real-World Safety and Outcomes
A 2026 study evaluated real-world SBRT outcomes for patients with centrally and ultra-centrally located early-stage NSCLC treated according to established planning principles. Separately, a 2024 analysis of a nationwide lung cancer audit reported that it was, to the authors’ knowledge, the largest real-world series of stage I NSCLC patients treated with SBRT with acute-toxicity and mortality data available. These studies focus on treatment as delivered in clinical practice and on outcomes relevant to patients.
Ongoing research is focused on optimizing treatment protocols, minimizing side effects, and personalizing SBRT based on individual patient characteristics. By addressing the challenges of credentialing and dosimetric optimization, we can ensure that all patients have access to the highest quality SBRT treatment, regardless of where they receive care.
The insights into the rectal V3600cGy, highlights the complexity in prostate SBRT planning. As this treatment modality continues to be developed, open research for dose prescriptions and best practice will be necessary.